PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 2, 2004, Pages 155-163

  Brouwers, Adrienne ^a   Verel, Iris ^b   Van Eerd, Julliëtte ^a   Visser, Gerard ^c   Steffens, Martijn ^a   Oosterwijk, Egbert ^a   Corstens, Frans ^a   Oyen, Wim ^a   Van Dongen, Guus ^b   Boerman, Otto ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

89Zr; Monoclonal antibody cG250; Positron emission tomography; Renal cell carcinoma, radioimmunoscintigraphy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CG250 N SUCCINYLDESFERRIOXAMINE B ZR 89; MONOCLONAL ANTIBODY CG250 PENTETATE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ZIRCONIUM; ZIRCONIUM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER LOCALIZATION; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; HUMAN CELL; IMMUNOSCINTIGRAPHY; ISOTOPE LABELING; KIDNEY CARCINOMA; METASTASIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOIMMUNOSCINTIGRAPHY; RADIOISOTOPE DISTRIBUTION; RAT; RAT STRAIN; SCINTILLATION CAMERA;

ANIMALS; ANTIBODIES, MONOCLONAL; CARCINOMA, RENAL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; KIDNEY NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOIMMUNODETECTION; RATS; RATS, NUDE; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZIRCONIUM;

EID: 2542488130     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804323071922     Document Type: Article

References (28)

1. Gambhir SS, Czemin J, Schwimmer J, et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:15.
2. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001;166:825.
3. Goldberg MA, Mayo Smith WW, Papanicolaou N, et al. FDG-PET characterization of renal masses: Preliminary experience. Clin Radiol 1997;52:510.
4. Safaei A, Figlin R, Hoh CK, et al. The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for restaging of renal cell cancer. Clin Nephrol 2002;57:56.
5. Verel I, Visser GWM, Boerman OC, et al. Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PET. Cancer Biother Radiopharm 2003;18:655.
6. Meijs WE, Herscheid JD, Haisma HJ, et al. Evaluation of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89. [abstr.] Int J Rad Appl Instrum 1992;43:1443.
7. Verel I, Visser GW, Boellaard R, et al. 89Zr immuno-PET: Comprehensive procedures for the production of (89)Zr-labeled monoclonal antibodies. J Nucl Med 2003;44:1271.
8. Mealey J. Turnover of carrier-free zirconium-89 in man. Nature 1957;179:674.
9. Roselli M, Schlom J, Gansow OA, et al. Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts. J Nucl Med 1989;30:672.
10. Muller WA, Schaffer EH, Linzner U. Studies on incorporated short-lived beta-emitters with regard to the induction of late effects. Radiat Environ Biophys 1980;18:1.
11. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 1986;38:489.
12. Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997;15:1529.
13. Grabmaier K, Vissers JL, De Weijert MC, et al. Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000; 85:865.
14. Uemura H, Nakagawa Y, Yoshida K, et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999;81:741.
15. Pastorekova S, Parkkila S, Parkkila AK, et al. Carbonic anhydrase IX, MN/CA IX: Analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997;112:398.
16. 89Zr for the labeling of antibodies with a positron emitter. Appl Radiat Isot 1994;45:1143.
17. Ruegg CL, Anderson-Berg WT, Brechbiel MW, et al. Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res 1990;50:4221.
18. Hnatowich DJ, Childs RL, Lanteigne D, et al. The preparation of DTPA-coupled antibodies radiolabeled with metallic radionuclides: An improved method. J Immunol Methods 1983;65:147.
19. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984;72:77.
20. Ebert T, Bander NH, Finstad CL, et al. Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res 1990;50:5531.
21. McDougal WS, Garnick MB. Comprehensive textbook of genitourinary oncology. In Vogelzang NJ, Scardino PT, Shipley WU, Coffey DS (Eds.). Lippincott, Williams, and Wilkins, Baltimore, 2000, p. 155.
22. 18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: A comparative study. Nucl Med Commun 2002;23:229.
23. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 2002;9:15.
24. 18F-FDG-PET in metastatic renal cell carcinoma - correlation with tumor aggressiveness? J Nucl Med 2000;41:117P.
25. 111In: An intrapatient comparison. Clin Cancer Res 2003;9(suppl.):3953S.
26. 186Re. J Nucl Med 2004;45:327.
27. Lee FT, Scott AM. Immuno-PET for tumor targeting. J Nucl Med 2003;44:1282.
28. Verel I, Visser GW, Boellaard R, et al. Quantitative (89)Zr immuno-PET for in vivo scouting of (90)Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003;44:1663.